Welcome to our dedicated page for Neogenomics news (Ticker: NEO), a resource for investors and traders seeking the latest updates and insights on Neogenomics stock.
NeoGenomics, Inc. (NASDAQ: NEO) is a cancer diagnostics company focused on oncology genetics testing and information services. This news page aggregates company announcements, conference presentations, financial updates, and other disclosures that relate to NeoGenomics’ role in precision oncology and testing laboratories.
Readers can find earnings and financial news, including quarterly and preliminary full-year revenue updates furnished through press releases and Form 8-K filings. These items describe trends in clinical test volumes, next-generation sequencing (NGS) revenue, and other aspects of the company’s oncology testing business.
The news feed also features scientific and clinical research updates. NeoGenomics regularly announces data presentations at major oncology and hematology meetings, such as the San Antonio Breast Cancer Symposium, the American Society of Hematology Annual Meeting, the International Society of Liquid Biopsy Annual Congress, and the European Society for Medical Oncology Congress. These updates often highlight molecular residual disease (MRD) studies using RaDaR assays, comprehensive genomic profiling in myeloid malignancies, and liquid biopsy-based genomic profiling across solid tumors.
In addition, investors and clinicians can follow corporate and governance developments, including board appointments, executive transitions, and participation in investor conferences. Together, these news items provide a view into how NeoGenomics advances its oncology diagnostics platforms, supports pharmaceutical partners and academic collaborators, and manages its public-company responsibilities. For ongoing insight into NEO stock-related developments and oncology testing initiatives, this page serves as a centralized news resource.
NeoGenomics (NASDAQ: NEO) has announced progress with a new version of its RaDaR® technology and resolved litigation with Natera regarding RaDaR 1.0. The company will host a business update conference call on September 24, 2024, at 8:30 a.m. ET.
The settlement with Natera is confidential but not material to the company's bottom line and does not impact its adjusted EBITDA guidance range or liquidity expectations. Investors can access the live webcast through the Investor Relations section of NeoGenomics' website or join the call via telephone using the provided dial-in numbers and access code.
NeoGenomics (NASDAQ: NEO) will present three studies at the ESMO Congress 2024 in Barcelona, showcasing advancements in cancer diagnostics using ctDNA and NGS. Key findings include:
1. NGS testing for 19 drug-targetable fusions can identify up to 4x more patients for matched therapies compared to testing.
2. A large-scale study on ctDNA in early-stage NSCLC identifies high-risk patients who may benefit from aggressive treatment.
3. A Phase II trial evaluating ctDNA as a marker for treatment decisions in high-risk melanoma patients.
These studies highlight the potential of advanced molecular diagnostics to improve early cancer detection and personalized treatment strategies.
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's top executives, including CEO Chris Smith, CFO Jeff Sherman, and CCO Warren Stone, will engage in an in-person fireside chat on Friday, Sept. 6, 2024, at 10:45 a.m. ET in New York City.
The presentation will be webcast live and can be accessed online through a provided link. For those unable to attend or watch live, a replay will be made available on the Investor Relations section of NeoGenomics' website at ir.neogenomics.com.
NeoGenomics (NASDAQ: NEO) reported strong Q2 2024 results, with consolidated revenue increasing 12% to $165 million. Clinical Services revenue grew 15% to $141 million, while Advanced Diagnostics revenue decreased 3% to $23 million. The company's net loss decreased 23% to $19 million, and Adjusted EBITDA increased 630% to positive $11 million.
Key highlights include:
- Clinical test volume up 6% year-over-year
- Average revenue per clinical test increased 9% to $454
- Gross profit margin at 44.1%, with Adjusted Gross Profit Margin at 47.3%
- Cash and cash equivalents totaled $388 million at quarter-end
NeoGenomics raised its full-year 2024 guidance, projecting revenue between $655-$667 million and Adjusted EBITDA of $33-$37 million.
NeoGenomics (NASDAQ: NEO), a premier oncology testing services company, will release its Q2 2024 financial results on July 29, 2024, after U.S. markets close. A webcast and conference call to discuss the financial outcomes and recent highlights are scheduled for 4:30 p.m. ET the same day. Interested parties can access the live webcast through the Investor Relations section on NeoGenomics' website, with a replay available afterward. For phone access, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) using the participant code 276062.
NeoGenomics (NASDAQ: NEO), a leader in oncology testing services, announced that Fort Myers’ Mayor Kevin Anderson will proclaim June as NeoGenomics’ Commitment to Cancer Month. This proclamation honors cancer survivors and those living with cancer. NeoGenomics, headquartered in Fort Myers, serves over 600,000 patients annually and aims to serve one million patients per year by 2028. The formal announcement will take place at the City Council meeting on June 17. CEO Chris Smith will attend to accept the honor. The proclamation acknowledges NeoGenomics' dedication to supporting cancer patients and survivors. This follows NeoGenomics' signing of the Working with Cancer Pledge, showcasing their support for team members affected by cancer or caring for loved ones with the disease.
NeoGenomics, a leader in oncology testing services, will unveil its comprehensive lung solutions and COMPASS® Hematopathology Services at the ASCO conference in Chicago from May 31 to June 4. Targeting the rise in cancer cases, the company emphasizes the importance of proper test selection for precision medicine. The new testing solutions include an early-stage NSCLC therapy panel, a 50-gene NGS panel, a liquid biopsy assay, and a 517-gene solid tumor test. NeoGenomics' COMPASS provides single-order, sample-to-diagnosis services for hematological malignancies, offering actionable insights for over 100 subtypes of leukemia, lymphoma, and myeloma. A poster presentation on gene reporting in solid tumor samples will also be featured.
NeoGenomics, Inc. (NASDAQ: NEO) reported a 14% increase in consolidated revenue to $156 million for the first quarter of 2024. Clinical Services revenue rose by 17% to $135 million, while Advanced Diagnostics revenue declined by 3% to $22 million. The net loss decreased by 12% to $27 million, with Adjusted EBITDA reaching positive $3 million, a 149% increase year-over-year.
Summary not available.
Summary not available.